Evidence map›Paper›PMID 23308211›Full record

ArticlePloS one2013

Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation.

András Iring, Éva Ruisanchez, Miriam Leszl-Ishiguro, Béla Horváth, Rita Benkő, Zsombor Lacza, Zoltán Járai, Péter Sándor, Vincenzo Di Marzo, Pál Pacher and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Function of Presynaptic Inhibitory Cannabinoid CBInternational journal of molecular sciences · 2024
    Article
  3. ΔCardiovascular toxicology · 2023
    Article
  4. Review
  5. Article
  6. Article
  7. Pharmacognosy and Effects of Cannabinoids in the Vascular System.ACS pharmacology & translational science · 2022
    Review
  8. Cannabinoids for Agitation in Alzheimer's Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Endocannabinoids in cerebrovascular regulation.American journal of physiology. Heart and circulatory physiology · 2016
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

András IringInstitute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary.
Éva Ruisanchez
Miriam Leszl-Ishiguro
Béla Horváth
Rita Benkő
Zsombor Lacza
Zoltán Járai
Péter Sándor
Vincenzo Di Marzo
Pál Pacher
Zoltán Benyó
Semmelweis University · HUNational Institutes of Health · USSzent Imre Egyetemi Oktatókórház · HU

Funding

Mechanism of oxidative/nitrosative stress and inflammation-induced tissue injuryZIAAA000375 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI PACHER, PAL · 2009 to 2025
$27.8M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundEndocannabinoids are among the most intensively studied lipid mediators of cardiovascular functions. In the present study the effects of decreased and increased activity of the endocannabinoid system (achieved by cannabinoid-1 (CB1) receptor blockade and inhibition of cannabinoid reuptake, respectively) on the systemic and cerebral circulation were analyzed under steady-state physiological conditions and during hypoxia and hypercapnia (H/H). METHODOLOGY/PRINCIPAL

findingsIn anesthetized spontaneously ventilating rats the CB1-receptor antagonist/inverse agonist AM-251 (10 mg/kg, i.v.) failed to influence blood pressure (BP), cerebrocortical blood flow (CoBF, measured by laser-Doppler flowmetry) or arterial blood gas levels. In contrast, the putative cannabinoid reuptake inhibitor AM-404 (10 mg/kg, i.v.) induced triphasic responses, some of which could be blocked by AM-251. Hypertension during phase I was resistant to AM-251, whereas the concomitant CoBF-increase was attenuated. In contrast, hypotension during phase III was sensitive to AM-251, whereas the concomitant CoBF-decrease was not. Therefore, CoBF autoregulation appeared to shift towards higher BP levels after CB1-blockade. During phase II H/H developed due to respiratory depression, which could be inhibited by AM-251. Interestingly, however, the concomitant rise in CoBF remained unchanged after AM-251, indicating that CB1-blockade potentially enhanced the reactivity of the CoBF to H/H. In accordance with this hypothesis, AM-251 induced a significant enhancement of the CoBF responses during controlled stepwise H/H. CONCLUSION/SIGNIFICANCE: Under resting physiological conditions CB1-receptor mediated mechanisms appear to have limited influence on systemic or cerebral circulation. Enhancement of endocannabinoid levels, however, induces transient CB1-independent hypertension and sustained CB1-mediated hypotension. Furthermore, enhanced endocannabinoid activity results in respiratory depression in a CB1-dependent manner. Finally, our data indicate for the first time the involvement of the endocannabinoid system and CB1-receptors in the regulation of the cerebral circulation during H/H and also raise the possibility of their contribution to the autoregulation of CoBF.

Indexed as

AnimalsArachidonic AcidsArterial PressureCerebrovascular CirculationEndocannabinoidsHeart RateHemodynamicsHypercapniaHypertensionHypoxiaLaser-Doppler FlowmetryMalePiperidinesPyrazolesRatsRats, WistarAM 251Arachidonic AcidsEndocannabinoidsN-(4-hydroxyphenyl)arachidonylamidePiperidinesPyrazolesReceptor, Cannabinoid, CB1

Identifiers

PMID23308211
PMCPMC3537620
OpenAlexW2060237574

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.